Xilio Therapeutics, Inc.

XLO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$58,241-$76,404-$88,222-$75,800
Dep. & Amort.$1,644$1,900$1,847$1,499
Deferred Tax$0$0$0$222
Stock-Based Comp.$6,434$0$0$4,958
Change in WC$31,782-$1,658$2,004-$11,803
Other Non-Cash$3$7,542$8,648$173
Operating Cash Flow-$18,378-$68,620-$75,723-$80,751
Investing Activities
PP&E Inv.-$36-$486-$1,867-$1,100
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$36-$486-$1,867-$1,100
Financing Activities
Debt Repay.-$3,382-$6,752-$85-$110
Stock Issued$6,825$202$16$116,359
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$25,753$0$0$144,419
Financing Cash Flow$29,196-$6,550-$69$260,668
Forex Effect$0-$25-$9$0
Net Chg. in Cash$10,782-$75,681-$77,668$178,817
Supplemental Information
Beg. Cash$46,291$120,385$198,053$20,789
End Cash$57,073$44,704$120,385$199,606
Free Cash Flow-$18,414-$69,106-$77,590-$81,851